A S F Lok

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Clinical utility in quantifying serum HBV DNA levels using PCR assays
    Chi Jen Chu
    J Hepatol 36:549-51. 2002
  2. ncbi request reprint The maze of treatments for hepatitis B
    Anna Suk Fong Lok
    N Engl J Med 352:2743-6. 2005
  3. ncbi request reprint Chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:507-39. 2007
  4. pmc Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C
    Anna S Lok
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 54:434-42. 2011
  5. ncbi request reprint Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B
    Anna S Lok
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Gastroenterology 143:619-28.e1. 2012
  6. doi request reprint HCV NS5A inhibitors in development
    Anna Suk-Fong Lok
    Division of Gastroenterology and Hepatology, University of Michigan Health System, University of Michigan, Ann Arbor, 48109, USA
    Clin Liver Dis 17:111-21. 2013
  7. pmc Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 136:138-48. 2009
  8. ncbi request reprint Hepatitis B infection: pathogenesis and management
    A S Lok
    Division of Gastroenterology, University of Michigan and Ann Arbor VA Medical Center, 48109, USA
    J Hepatol 32:89-97. 2000
  9. ncbi request reprint Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management
    Anna S Lok
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 46:254-65. 2007
  10. ncbi request reprint Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007

Detail Information

Publications85

  1. ncbi request reprint Clinical utility in quantifying serum HBV DNA levels using PCR assays
    Chi Jen Chu
    J Hepatol 36:549-51. 2002
  2. ncbi request reprint The maze of treatments for hepatitis B
    Anna Suk Fong Lok
    N Engl J Med 352:2743-6. 2005
  3. ncbi request reprint Chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:507-39. 2007
  4. pmc Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C
    Anna S Lok
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 54:434-42. 2011
    ..7% of controls. HBV DNA was detected in the serum of only one control subject and no patients with HCC. HBV DNA (as a marker of occult HBV infection) was detected in the livers of 10.7% of HCC cases and 23.6% of controls (P=0.18)...
  5. ncbi request reprint Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B
    Anna S Lok
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Gastroenterology 143:619-28.e1. 2012
    ..We compared the efficacy and safety of ETV monotherapy with those of a combination of ETV and TDF...
  6. doi request reprint HCV NS5A inhibitors in development
    Anna Suk-Fong Lok
    Division of Gastroenterology and Hepatology, University of Michigan Health System, University of Michigan, Ann Arbor, 48109, USA
    Clin Liver Dis 17:111-21. 2013
    ....
  7. pmc Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 136:138-48. 2009
    ..We evaluated the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) cohort for the incidence of HCC and associated risk factors...
  8. ncbi request reprint Hepatitis B infection: pathogenesis and management
    A S Lok
    Division of Gastroenterology, University of Michigan and Ann Arbor VA Medical Center, 48109, USA
    J Hepatol 32:89-97. 2000
    ....
  9. ncbi request reprint Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management
    Anna S Lok
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 46:254-65. 2007
    ..Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy...
  10. ncbi request reprint Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
    ....
  11. ncbi request reprint Chronic hepatitis B: update of recommendations
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Hepatology 39:857-61. 2004
  12. ncbi request reprint Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
    Hepatology 42:282-92. 2005
    ..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
  13. ncbi request reprint New treatment of chronic hepatitis B
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109, USA
    Semin Liver Dis 24:77-82. 2004
    ..Thus, new treatments that have more potent antiviral effects, less toxicity, and minimal or no risk of resistance are needed. This article will focus on new antiviral agents that are being evaluated in clinical trials...
  14. ncbi request reprint Navigating the maze of hepatitis B treatments
    Anna Suk Fong Lok
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 132:1586-94. 2007
  15. ncbi request reprint Hepatitis B: liver fibrosis and hepatocellular carcinoma
    A S F Lok
    Division of Gastroenterology and Hepatology, University of Michigan Health System, 3912, Taubman Center, SPC 5362, 1500 E, Medical Center Drive, Ann Arbor, MI 48109, USA
    Gastroenterol Clin Biol 33:911-5. 2009
    ..These data indicate that algorithms incorporating demographics, viral factors, degree of necroinflammation and extent of fibrosis may be more accurate in predicting the risk of HBV-related HCC than fibrosis staging alone...
  16. ncbi request reprint Prevention of recurrent hepatitis B post-liver transplantation
    Anna S F Lok
    University of Michigan, Ann Arbor, MI, USA
    Liver Transpl 8:S67-73. 2002
    ..6. Lamivudine resistance before LT is associated with an increased risk for recurrent hepatitis B post-LT. 7. A cost-effective prophylactic regimen to prevent recurrent hepatitis B should be tailored according to risk...
  17. ncbi request reprint Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
    A S Lok
    Division of Gastroenterology, University of Michigan and VA Medical Center, Ann Arbor, MI, USA
    Hepatology 32:1145-53. 2000
    ..Additional changes in other parts of the HBV genome may restore the replication fitness of lamivudine-resistant mutants...
  18. ncbi request reprint Liver transplantation in patients with hepatitis B virus infection: outcome in Asian versus white patients
    E K Teo
    University of Michigan Medical Center, Ann Arbor, MI, USA
    Hepatology 34:126-32. 2001
    ..However, Asians with recurrent HBV infection posttransplantation had significantly higher mortality...
  19. pmc Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 140:840-9; quiz e12. 2011
    ..We investigated whether peginterferon decreases the incidence of HCC in the HALT-C cohort over a longer posttreatment follow-up period...
  20. ncbi request reprint Prevention of hepatitis B virus-related hepatocellular carcinoma
    Anna S F Lok
    of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Gastroenterology 127:S303-9. 2004
    ..In addition, questions on who to treat and how long treatment should be administered must be addressed before recommendations on the use of antiviral therapy to prevent HBV-related HCC can be made...
  21. pmc Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 138:493-502. 2010
    ..The aim of this study was to compare the accuracy of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) in the early diagnosis of HCC...
  22. pmc Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
    ..15, 95% CI = 0.06-0.38) or HCC (HR = 0.19, 95% CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR...
  23. ncbi request reprint Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States
    C T Wai
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    J Viral Hepat 12:192-8. 2005
    ..Further studies are needed to determine if HBV genotypes play a role in the outcome of acute HBV infection...
  24. pmc Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Am J Gastroenterol 105:1551-60. 2010
    ....
  25. pmc Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list
    Melissa K Osborn
    University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Clin Gastroenterol Hepatol 5:1454-61. 2007
    ..Use of antiviral salvage therapy might decrease this risk...
  26. doi request reprint Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations
    Jessica Tan
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 48:391-8. 2008
    ..We sought to identify mutations associated with treatment failure to adefovir (ADV) and to determine virologic response to tenofovir (TDF) alone and in combination with emtricitabine (FTC) in these patients...
  27. ncbi request reprint Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 43:937-43. 2005
    ..The aim of this study was to describe the clinical course of patients with adefovir-resistant HBV infection...
  28. pmc Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA
    Am J Gastroenterol 103:2766-75. 2008
    ..The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin...
  29. ncbi request reprint Combination of HBIG and lamivudine-resistant mutations: a formula for trouble?
    Robert J Fontana
    Division of Gastroenterology University of Michigan Medical School Ann Arbor, MI, USA
    Liver Transpl 8:1082-4. 2002
  30. ncbi request reprint Treatment of chronic hepatitis B: who to treat, what to use, and for how long?
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 2:839-48. 2004
    ..Duration of treatment is at least 1 year with lamivudine and adefovir; longer duration of treatment is needed in most patients, but the optimal duration of treatment and the criteria for stopping treatment have not been established...
  31. ncbi request reprint Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy
    Stephen N Wong
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:374-81. 2007
    ..Maintenance therapy with NA after discontinuation of long-term HBIG therapy is associated with a low risk of HBV recurrence after OLT in compliant HBV patients...
  32. pmc Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation
    B Degertekin
    University of Michigan Health System, Ann Arbor, MI, USA
    Am J Transplant 10:1823-33. 2010
    ..In conclusion, low rates of HBV recurrence can be accomplished with all the HBIG regimens used when combined with antiviral therapy including patients with breakthrough pre-OLT as long as rescue therapy is administered pre- and post-OLT...
  33. pmc Characteristics of chronic hepatitis B patients who underwent liver biopsies
    W Chotiyaputta
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    J Viral Hepat 18:792-803. 2011
    ....
  34. ncbi request reprint Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma
    Stephen N Wong
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:334-42. 2007
    ..In conclusion, despite more advanced liver disease and a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC, possibly related to beneficial effects of antiviral therapy...
  35. pmc Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir
    Munira Hussain
    Division of Gastroenterology, University of Michigan Medical Center, 1500 East Medical Center Drive, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109 0362, USA
    J Clin Microbiol 44:1094-7. 2006
    ..Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier...
  36. ncbi request reprint Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine and the Consortium for Health Outcomes Innovation and Cost Effectiveness Studies, University of Michigan Medical School, Ann Arbor, MI 48109 0362, USA
    Psychosomatics 43:378-85. 2002
    ..Because of its brevity and simplicity, the Brief Symptom Inventory may prove to be a useful adjunct to clinician assessment in detecting and monitoring emotional distress during interferon-alpha treatment of chronic hepatitis C...
  37. ncbi request reprint Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Hepatology 44:1675-84. 2006
    ..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
  38. ncbi request reprint Virologic response and resistance to adefovir in patients with chronic hepatitis B
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    J Hepatol 44:283-90. 2006
    ..The incidence and risk factors for adefovir-resistant HBV have not been clearly defined...
  39. pmc Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  40. ncbi request reprint Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
    J Hepatol 43:434-41. 2005
    ..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy...
  41. ncbi request reprint Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Liver Transpl 8:433-9. 2002
    ....
  42. ncbi request reprint HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C
    Chun Tao Wai
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Hepatology 36:1425-30. 2002
    ..Stratification for HBV genotypes should be considered in future clinical trials of antiviral therapy of chronic hepatitis B...
  43. ncbi request reprint Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice
    Thomas M Shehab
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
    Clin Gastroenterol Hepatol 2:425-31. 2004
    ....
  44. doi request reprint Re-weighting the model for end-stage liver disease score components
    Pratima Sharma
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 135:1575-81. 2008
    ..We re-estimated MELD coefficients and evaluated the effect of updated MELD on the liver transplant waiting list ranking...
  45. doi request reprint Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs
    W Chotiyaputta
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA
    J Viral Hepat 19:205-12. 2012
    ..Patients with chronic hepatitis B with better adherence to NUC therapy had a trend towards a lower rate of viral breakthroughs...
  46. doi request reprint Endpoints of hepatitis B treatment
    W Chotiyaputta
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA
    J Viral Hepat 17:675-84. 2010
    ..This review will discuss the validity of these intermediate endpoints as surrogates of clinical endpoints, and the rates at which these intermediate endpoints can be achieved with currently available therapies...
  47. ncbi request reprint Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C
    Linas A Bieliauskas
    Neuropsychology Section, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan 48105, USA
    J Int Neuropsychol Soc 13:687-92. 2007
    ..It is important to account for CRS when assessing cognitive findings in large-scale clinical trials...
  48. ncbi request reprint Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation
    Michael L Volk
    Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 135:1568-74. 2008
    ..We aimed to determine whether implementation of MELD affected the quality of organs transplanted, the type of patients who receive the higher-risk organs, and the impact of these changes on their posttransplant survival...
  49. doi request reprint How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Hospitals, Ann Arbor, Michigan 48109, USA
    Liver Transpl 14:S8-S14. 2008
    ..Occurrence of antiviral drug resistance can be reduced by the use of the most potent nucleos(t)ide analogue(s) with the highest genetic barrier to resistance, emphasis of medication compliance, and close monitoring of virologic response...
  50. pmc Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 7:219-26. 2009
    ..Serum fibrosis marker levels during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were determined...
  51. ncbi request reprint Newer markers for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 127:S113-9. 2004
    ..There is an urgent need for novel biomarkers for the detection of early HCC; the National Cancer Institute proposal provides a framework for future validation studies...
  52. ncbi request reprint Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:1154-63. 2007
    ..Nonetheless, the frequency of cognitive impairment did not increase during the first 24 weeks of treatment in 177 patients (34% versus 32%, P=0.64) nor in the 57 patients completing 48 weeks of treatment (P=0.48, ANOVA)...
  53. ncbi request reprint Public health impact of antiviral therapy for hepatitis C in the United States
    Michael L Volk
    Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, USA
    Hepatology 50:1750-5. 2009
    ..Results from the NHANES questionnaire suggest that the primary barrier to treatment is lack of diagnosis, with 69/133 (adjusted proportion 49%) of respondents previously unaware that they had hepatitis C...
  54. ncbi request reprint Emotional distress in chronic hepatitis C patients not receiving antiviral therapy
    Robert J Fontana
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 36:401-7. 2002
    ..The aim of our study was to determine the prevalence, type, and severity of emotional distress in a large group of consecutive chronic hepatitis C (CHC) patients not receiving anti-viral therapy...
  55. ncbi request reprint High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Clin Gastroenterol 34:177-82. 2002
    ..Kinetic studies have demonstrated a more rapid reduction in hepatitis C virus (HCV) RNA levels among patients taking high daily doses of interferon compared with those taking standard-dose interferon...
  56. pmc Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    J Clin Microbiol 40:3729-34. 2002
    ....
  57. ncbi request reprint Chronic hepatitis B
    Anna S F Lok
    University of Michigan, Ann Arbor, MI 48109, USA
    N Engl J Med 346:1682-3. 2002
  58. pmc Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
    Gut 59:1401-9. 2010
    ..The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC)...
  59. ncbi request reprint Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109 0362, USA
    Gastroenterology 125:1714-22. 2003
    ..The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment...
  60. doi request reprint Beyond utilitarianism: a method for analyzing competing ethical principles in a decision analysis of liver transplantation
    Michael L Volk
    Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Med Decis Making 28:763-72. 2008
    ..In this study, the authors examine a method to incorporate competing ethical principles in a decision analysis of liver transplantation for a patient with acute liver failure (ALF)...
  61. ncbi request reprint Treatment of hepatitis B
    Chun Tao Wai
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109 0362, USA
    J Gastroenterol 37:771-8. 2002
    ..This review updates safety and efficacy data of interferon alpha and lamivudine in the treatment of chronic hepatitis B. Management strategies in different clinical scenarios and future treatments are also discussed...
  62. ncbi request reprint Management of hepatitis B patients with antiviral resistance
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, Mich, USA
    Antivir Ther 9:1013-26. 2004
    ..The ideal approach is to prevent antiviral resistance through judicious use of antiviral therapy and the use of more potent antiviral agents, possibly in combination...
  63. ncbi request reprint Hepatitis B virus variants
    Watcharasak Chotiyaputta
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USA
    Nat Rev Gastroenterol Hepatol 6:453-62. 2009
    ....
  64. ncbi request reprint Update on viral hepatitis in 2004
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, 48109, USA
    Curr Opin Gastroenterol 21:300-7. 2005
    ..Studies reporting novel and clinically relevant findings were selected after a PubMed search. The aim is to provide an up-to-date summary of important developments in viral hepatitis...
  65. ncbi request reprint Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
    Chi Jen Chu
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI, USA
    Hepatology 36:1408-15. 2002
    ..Given the fluctuating course of HBeAg-negative chronic hepatitis, it is not possible to define a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis...
  66. ncbi request reprint Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation
    Munira Hussain
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:1137-44. 2007
    ..Our findings suggest that occult HBV reinfection occurs in most HBV patients after OLT and continued administration of appropriate prophylactic therapy is important in preventing overt HBV recurrence...
  67. ncbi request reprint Natural history of hepatitis B and outcomes after liver transplantation
    Mary Ann Huang
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
    Clin Liver Dis 7:521-36. 2003
    ....
  68. ncbi request reprint Update on viral hepatitis: 2005
    Stephen N Wong
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, 48109, USA
    Curr Opin Gastroenterol 22:241-7. 2006
    ..This review aims to provide a concise summary of relevant developments in the treatment and prevention of viral hepatitis based on publications between December 2004 and November 2005...
  69. pmc Variation in organ quality between liver transplant centers
    M L Volk
    Division of Gastroenterology and Hepatology, University of Michigan, MI, USA
    Am J Transplant 11:958-64. 2011
    ..10 per 0.1 increase in mean DRI). In conclusion, the quality of deceased donor organ patients receive is variable and depends in part on the characteristics of the transplant center they visit...
  70. doi request reprint Update on viral hepatitis: 2007
    Bulent Degertekin
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Curr Opin Gastroenterol 24:306-11. 2008
    ..This is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2006 and November 2007...
  71. ncbi request reprint Evolution of multi-drug resistant hepatitis B virus during sequential therapy
    Hyung Joon Yim
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 44:703-12. 2006
    ..De novo combination therapy may prevent the emergence of multi-drug resistant mutants...
  72. ncbi request reprint Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B
    Scott K Fung
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Nat Clin Pract Gastroenterol Hepatol 1:90-7. 2004
    ..Several other nucleoside and nucleotide analogs are being evaluated in phase II/III clinical trials for hepatitis B...
  73. ncbi request reprint Management of patients with hepatitis B virus-induced cirrhosis
    Scott K Fung
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 42:S54-64. 2005
  74. ncbi request reprint Noninvasive monitoring of patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USA
    Hepatology 36:S57-64. 2002
    ..There is an urgent need to develop and validate noninvasive tests that can accurately reflect the full spectrum of hepatic inflammation and fibrosis in chronic hepatitis C...
  75. doi request reprint Indications for therapy in hepatitis B
    Bulent Degertekin
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA
    Hepatology 49:S129-37. 2009
    ..All patients who are not initiated on treatment should continue to be monitored so treatment can be started if and when the indication arises...
  76. ncbi request reprint Update on viral hepatitis: 2006
    Jessica Tan
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Curr Opin Gastroenterol 23:263-7. 2007
    ..This is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2005 and November 2006...
  77. pmc Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants
    Munira Hussain
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    J Clin Microbiol 41:3699-705. 2003
    ..INNO-LiPA is rapid, sensitive, and reliable-thus enabling accurate determination of HBV genotypes and detection of PC and CP variants in a large population of patients...
  78. ncbi request reprint Hepatitis B: progress in the last decade
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, USA
    Semin Liver Dis 23:1-4. 2003
  79. ncbi request reprint Identification and management of hepatitis C patients in primary care clinics
    Thomas M Shehab
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Am J Gastroenterol 98:639-44. 2003
    ..Previous survey-based research suggested that hepatitis C patients receive suboptimal care in primary care settings. The aim of our study was to define the actual level of care hepatitis C patients receive in primary care clinics...
  80. ncbi request reprint Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C
    Chi Jen Chu
    Division of Gastroenterology, Department of Medicine, University of Michigan and VA Medical Center, Ann Arbor, Michigan, USA
    Gastroenterology 122:1756-62. 2002
    ..The aim of our study was to determine if HBV genotype B is associated with higher rates of spontaneous hepatitis B e antigen (HBeAg) seroconversion compared with genotype C...
  81. pmc A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA
    Ying Liu
    Division of Gastroenterology, University of Michigan Medical Center, 1500 East Medical Center Dr, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109 0362, USA
    J Clin Microbiol 45:553-8. 2007
    ..We have established a real-time PCR assay that is genotype independent and can accurately quantify a wide range of HBV DNA levels. Further studies of additional samples are ongoing to validate the genotype independence of our assay...
  82. ncbi request reprint Hepatitis B virus genotypes in the United States: results of a nationwide study
    Chi Jen Chu
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 125:444-51. 2003
    ..The aims of this nationwide study were to determine the prevalence of HBV genotypes in the United States and the association between HBV genotypes and patient demographics, mode of infection, and clinical status...
  83. ncbi request reprint Prevalence of HBV precore/core promoter variants in the United States
    Chi Jen Chu
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Hepatology 38:619-28. 2003
    ..Physicians should be aware of the existence of HBV precore and core promoter variants and the clinical condition of "HBeAg-negative chronic hepatitis."..
  84. ncbi request reprint Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005
    Hyung Joon Yim
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 43:S173-81. 2006
    ..Newer antiviral therapies with improved efficacy and decreased risk of resistance may lead to a complete revision of the chapter on the natural history of chronic HBV infection on the occasion of the golden jubilee of Hepatology...
  85. ncbi request reprint Management of chronic hepatitis B
    Hari S Conjeevaram
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 38:S90-103. 2003

Research Grants3

  1. RECURRENT HEPATITIS B AFTER LIVER TRANSPLANTATION
    Anna Lok; Fiscal Year: 2007
    ..abstract_text> ..
  2. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    ..abstract_text> ..
  3. Hepatitis B Clinical Research Network Clinical Center: Michigan-Hawaii consortium
    Anna Lok; Fiscal Year: 2008
    ..Clinical trials on other important topics such as treatment of patients in the immune tolerance phase and optimal management of patients with antiviral-resistant HBV are also discussed. ..